Loading company…
Telara Pharma is developing cilastatin-based treatments for acute kidney injury and other inflammatory disorders.
Founded in 2020 and based in Madrid, Telara Pharma is developing cilastatin for severe inflammatory disorders, particularly acute kidney injury. In May 2021, it raised EUR 100,000 in Seed funding led by Genesis Biomed to advance development. The company is also exploring programs for neuroinflammatory disorders.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in